Core Laboratories Inc. (CLB) reported that Mark Damian Tattoli, SVP, Gen Counsel & Secretary, had a derivative exercise/conversion involving 700 restricted shares, reported as disposed, and acquired 700 common shares on October 1, 2026. On the same date, 276 common shares were delivered or withheld for payment of exercise price or tax liability; the reported price was $9.76 per share. No Rule 10b5-1 plan is reported.
The restricted shares vest annually over six years on the grant anniversary, subject to continuous service. Reported holdings following the transaction included 250 restricted shares, plus indirect common-stock holdings of 20 shares in a custodial account and 1,695 shares in a 401 (k) Plan.
Core Laboratories Inc. (CLB) reported that its CAO & Treasurer, Sow Hang Teo, disposed of 250 restricted shares in an exercise/conversion and acquired 250 common shares on October 1, 2026. He also reported 99 common shares delivered or withheld for payment of exercise price or tax liability; the reported price was $9.76 per share. After the derivative transaction, 6,000 restricted shares were reported, including multiple grants. The awards vest annually over six years, subject to continuous service on each vesting date. No Rule 10b5-1 plan is reported.
Core Laboratories Inc. (CLB) reports that director Kwaku Temeng has resigned from the Board of Directors, effective October 1, 2026. He currently serves as Chairman of the Nominating Committee and as a member of the Compensation Committee.
Temeng informed the Board verbally on August 19, 2026 and confirmed by letter on August 25, 2026. His letter states that the resignation is due to a disagreement with the Board regarding the Company’s strategic direction and certain governance practices. The Board believes his primary disagreement involves how succession planning is being conducted and concerns about the Company’s research priorities. His resignation letter is included as an exhibit, and the Company notes his more than five years of service and contributions.
Disciplined Growth Investors, Inc. reported its beneficial ownership of common shares of Core Laboratories Inc. as of 06/30/2026. The firm beneficially owns 3,042,177 common shares, representing 6.6% of the class. It has sole voting power over 2,961,959 shares and sole dispositive power over all 3,042,177 shares, with no shared voting or dispositive power indicated. This reflects a significant institutional stake held and controlled solely by Disciplined Growth Investors, Inc.
Ariel Investments, LLC reports significant ownership in Core Laboratories Inc common stock. Ariel beneficially owns 14,074,945 shares, representing 30.5% of the outstanding common stock as of June 30, 2026. Ariel has sole voting power over 13,141,081 shares and sole dispositive power over 14,074,945 shares, with no shared voting or dispositive power.
Ariel’s advisory clients are entitled to receive dividends and sale proceeds for all securities reported. Ariel Fund, a series of Ariel Investment Trust, owns 6,474,663 shares of Core Laboratories, which represents an economic interest in more than 5% of the class.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Core Laboratories Inc. BlackRock reports beneficial ownership of 3,811,390 shares, representing 8.3% of the common stock. It has sole voting power over 3,703,577 shares and sole dispositive power over 3,811,390 shares, with no shared voting or dispositive power reported. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Core Laboratories’ outstanding common shares.
Core Laboratories Inc. reported that Chairman and CEO Bruno Lawrence purchased 5,000 shares of common stock on July 31, 2026 at $10.78 per share, described as a purchase in open market or private transaction. After this trade, his directly held stake totaled 262,438 shares.
Core Laboratories CAO & Treasurer Teo Sow Hang exercised 440 Restricted Shares into Common Stock on August 1, 2026, and disposed of 198 Common shares at $10.64 per share to pay the exercise price or tax liability. The Restricted Shares vest annually over six years and reflect multiple grants.
Core Laboratories executive Mark Damian Tattoli exercised restricted share awards for 250 underlying common shares at $0 on 1 August 2026. The related restricted shares were canceled and 99 common shares were disposed of at $10.64 per share as payment of exercise price or tax liability. Following these transactions he holds 950 restricted shares directly, plus indirect common stock positions of 20 shares in a custodial account and 1,694.8420 shares in a 401 (k) Plan. These transactions were not reported under a Rule 10b5-1 trading plan.
Core Laboratories Inc. generated revenue of $124,609 thousand for the quarter ended June 30, 2026, down 4% from the prior-year period. Services contributed $94,277 thousand and product sales $30,332 thousand. Operating income declined to $9,151 thousand, and net income attributable to the company fell to $5,956 thousand, or diluted EPS of $0.13.
For the first six months of 2026, revenue was $246,406 thousand and net income attributable to Core Laboratories was $5,167 thousand. Net cash provided by operating activities totaled $11,774 thousand, while capital expenditures were $10,659 thousand. Long-term debt stood at $116,375 thousand with a leverage ratio of 1.30 and interest coverage of 6.53; the current ratio was 2.12:1, and available borrowing capacity under the credit facility was approximately $85.6 million.
Management highlights ongoing geopolitical conflicts in the Middle East and Russia–Ukraine region, noting a 15% to 20% reduction in global cargo movement of crude oil and derived products in the second quarter of 2026 versus a year earlier, which is reducing demand for certain laboratory assay services, though large international projects are described as more resilient.